The 2 Faces of JNK Signaling in Cancer
Genes & Cancer · 01.09.2013 · 4 (9-10) · 397-400
DOI: 10.1177/1947601913486349 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes & Cancer, online erschienen am 12.04.2013. Verfasst von Cathy Tournier. Beteiligte Einrichtung: University of Manchester, Manchester, UK. Die Arbeit wurde bisher 160-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
c-Jun NH2-terminal kinase (JNK) was discovered almost 20 years ago as the protein kinase responsible for phosphorylating c-Jun at Ser-63 and Ser-73. These sites had previously been demonstrated to be essential for the stimulation of c-Jun activity and for cooperation with Ha-ras in oncogenic transformation. This led to the idea that JNK was a positive regulator of cellular transformation. However, the analysis of jnk gene deletion in various mouse models of cancer has produced conflicting findings, with some studies supporting the pro-oncogenic function of JNK and others providing evidence that JNK acts as a tumor suppressor. This review will discuss how these unexpected findings have increased our understanding of the role of JNK signaling in cancer and have provided a source of new working hypotheses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Manchester, Manchester, UK.
Zitieren
APA
Tournier, C. (2013). The 2 Faces of JNK Signaling in Cancer. Genes & Cancer, 4(9-10), 397-400. https://doi.org/10.1177/1947601913486349
Vancouver
Tournier C. The 2 Faces of JNK Signaling in Cancer. Genes & Cancer. 2013;4(9-10):397-400. doi:10.1177/1947601913486349
BibTeX
@article{Tournier2013,
author = {Tournier, Cathy},
title = {The 2 Faces of JNK Signaling in Cancer},
journal = {Genes & Cancer},
year = {2013},
volume = {4},
number = {9-10},
pages = {397--400},
doi = {10.1177/1947601913486349}
}
EUVIMED